Semax mentions in clinic notes are rising for cognition and stress

Semax is a lab-made peptide that has a longer research record in Russia, where it is registered as an intranasal medicine for ischemic stroke ². In the United States it is not FDA-approved and is sold directly to consumers, often for cognition, mood, and stress resilience ¹. Because products bought outside regulated pharmacies rarely appear in structured medication lists, a research team looked for evidence in the free text of clinical notes instead.

The team used large language models to scan de-identified notes from the nference federated data network for mentions of Semax and Selank. Then physicians manually reviewed the model's judgments. This kind of study does not test whether a peptide works. It counts how often the words appear in medical records and whether trained physicians agree that the notes describe actual use ¹.

Among 43 patients with a Semax mention in their notes, the model and manual review confirmed actual use in 22 patients, or 51 percent. For Selank, 27 of 39 patients had confirmed use, about 69 percent. Physician adjudication agreed with the model's classification in 164 of 165 individual note-level assessments, a 99.4 percent agreement rate ¹.

These numbers are small, but they show that both human reviewers and a well-trained language model can read the notes consistently. A high agreement rate matters because it means the study is measuring something real rather than random word matches ¹.

Across the pooled group of 49 patients with confirmed use of either peptide, the notes listed reasons that fell into clear categories. Cognitive enhancement was the most common at 28.6 percent, tied with mood, anxiety, or stress support at 28.6 percent. Smaller groups mentioned energy or performance, sleep, musculoskeletal problems, and gastrointestinal problems. A separate manual review agreed with the model's reason labels in 86.7 percent of cases ¹.

The notes also showed that 37 percent of documented use was intranasal, and some notes mentioned stacking, though the source does not list the other products involved ¹. This pattern matches how direct-to-consumer peptide products are often marketed, but the study did not collect data on whether the patients improved.

Before this, most Semax research came from controlled clinical or preclinical settings. In Russia, Semax is registered as an intranasal medicine for ischemic stroke, and studies have reported neurological recovery when Semax was added to standard stroke care ². Small eye clinic studies have also reported no adverse reactions over a month in glaucoma patients and functional gains in optic neuropathy ⁵.

These earlier studies started with a diagnosis and measured a specific outcome. The new note study starts from the opposite direction. It finds Semax in routine US clinical notes and asks what patients said they were using it for. The answer is not stroke care. It is cognition and mood or stress, which aligns with how these products are marketed direct to consumers ¹.

The study reported an average quarter-over-quarter growth of 14 percent for Semax and 16 percent for Selank over the past year ¹. That sounds like rapid growth. But the base is small: only 49 confirmed users across both peptides. Percent change can be misleading with small numbers. The important finding is that documentation exists and is growing, not that use is widespread.

The study also does not provide any effectiveness data. It did not track changes in memory, mood, or stress scores after use. It only recorded that a note said the patient used the peptide and why. This kind of evidence is useful for watching how unapproved products spread through routine care, but it cannot support a claim that Semax helps cognition or mood ¹.

The study leaves open several important questions. It does not know whether the documented use continued, whether side effects occurred, or whether the patients improved. It cannot tell whether the Semax products people bought matched what was studied in earlier Russian trials. It also cannot separate a true increase in use from better note-taking by doctors or more complete scanning by language models. And it does not compare Semax with any standard treatment for cognition or mood. In the research so far, Semax is appearing more often in clinical notes, but that counts documentation, not proof of benefit.